Psychoactive Substances Bill [HL]

Lord Paddick Excerpts

Tuesday 23rd June 2015 Lords Chamber

Moved by

[Lord Paddick]

1: Clause 1, page 1, line 3, after “about” insert “reviewing the Misuse of Drugs Act 1971 and”

[Lord Paddick (LD)]

My Lords, I will speak also to the other amendments in my name and that of my noble friend Lady Hamwee in this group. This group is fundamental to our debate on the rest of the Bill, as it asks the Government whether they are really committed to an evidence-based approach to combating drugs—basically, whether they are committed to doing what works in practice.

Amendment 1 is a minor amendment which sets out our proposals in the overall context of the Bill. The key amendment is Amendment 5, which would require the Secretary of State to commission an “independent evidence-based review” of the Misuse of Drugs Act 1971 and its implementation, and to publish the results. Amendments 111, 112 and 115 would ensure that this review had to take place before the rest of the provisions in the Bill came into force. If, in the face of the evidence that such a review would produce, the Government were still determined to press ahead with this, so be it. However, our amendments would give the Government time to consider whether a different approach, based on evidence of what works, would produce the outcomes we all seek.

I will be clear: the Liberal Democrats are as concerned about the harm caused by the misuse of drugs in general, and the misuse of new psychoactive substances in particular, as anyone else in this House, including the Government. Liberal Democrats want what parents and families want. Parents want their children to avoid taking drugs. The evidence suggests that education, rather than criminalisation, is more likely to achieve that end. If their children use drugs, they do not want them to be harmed by taking them, let alone be killed by them. The evidence suggests that the best way to do that is through education and concentrating resources on the drug dealers, not the users. If their children use drugs, the last thing they want is for the rest of their children’s lives to be ruined by a criminal record for simply having small amounts of a relatively harmless substance on them. Educate them if they are being reckless, and if they are addicted, treat them.

Our concern, borne out by the evidence from other countries, is that prohibition and the criminalisation of drug users do not reduce the harm caused by drugs. They do not save lives, reduce addiction or deal with the serious criminality associated with drugs, such as the violence associated with drug dealing. Our concern is that the Bill—yet another Bill based on prohibition and criminalisation—will not only be ineffective in reducing the considerable harm caused by new psychoactive substances but will increase that harm, cost more lives, increase addiction and boost the profitability of drug dealing.

I expect the Government to say that they do not believe this will be the case, and that they have a manifesto commitment to enact this legislation—and of course under the Salisbury convention we on these Benches will not try to wreck the Bill. What we are asking for is an independent, evidence-based review of how effective current legislation is in achieving what it sets out to achieve—that is, a review of the Misuse of Drugs Act 1971—before we give effect to another piece of legislation which is very similar to that.

I can tell noble Lords that making drugs illegal is not an effective deterrent, and that the classification of drugs under the Misuse of Drugs Act lacks a sound scientific basis in the case of many of the drugs listed in that legislation, and therefore it lacks credibility in the eyes of those whom the system of classification is designed to deter. However, rather than taking my word for it, I ask the House to support an independent review. We are not asking for a major piece of new research but for a similar exercise to that carried out recently by David Anderson into the far more complex area of surveillance, which he completed in less than 12 months. We are not trying to delay the passing of this legislation, just asking that we hold back from giving effect to it until after the review has been conducted. It may well be that, having seen the review, the Government decide to adopt a different approach.

The Liberal Democrats want a health-based and harm reduction-based approach to dealing with the problems caused by the misuse of drugs. If I thought that making even more drugs illegal would save one life or stop one person becoming addicted, I would not be asking for this review. Therefore, will the Minister commit to having such a review so we can ensure that, before this Bill comes into force, we learn the lessons of the past? I beg to move.

--- Later in debate ---

[Lord Brown of Eaton-under-Heywood (CB)]

My Lords, I am puzzled. Somebody has lost the plot and it is probably me. I do not see why this has to delay the legislation at all. I follow that in this group, Amendment 115—the last one—would indeed delay the legislation. It involves an insertion into Clause 57, which is about commencement. However, I do not think that applies to any of the other amendments. On the face of it, Amendment 5 seems to demand the implementation of the Bill. How would one review its implementation under proposed new subsection (1)(b), except by bringing it into force and letting it go ahead? Unless someone can explain why Amendment 115 within this group necessarily has to be passed, I do not see that any delay at all is involved.

[Lord Paddick]

My Lords, if I may assist the Committee, clearly these amendments can be taken separately and, if the Committee is minded to say that there needs to be a review and no delay in giving effect to the legislation, that is a matter for the Committee. We are talking about the Misuse of Drugs Act in that amendment rather than the Bill, if that helps the noble Lord.

[Baroness Meacher]

I wonder if it might help the Committee if the noble Lord withdrew Amendment 115 simply so that we can debate the need for a review of the Misuse of Drugs Act without setting it in the context of a delay to the psychoactive substances ban.

--- Later in debate ---

[The Minister of State, Home Office (Lord Bates) (Con)]

My Lords, first, I welcome the amendment and the way in which it was proposed by the noble Lord, Lord Paddick, because it has sparked a genuine debate, one of real high quality and passion on all sides of the argument. I thought that the arguments in the contributions we heard were pretty finely balanced for and against. I want to try to respond to some of those points. The point made by the noble Baroness, Lady Bakewell, relating to Ireland is an example worth looking at. That issue comes up in a later group of amendments and I will be happy to respond in more detail at that point, if I can.

I want to pick up on the comments made by my noble and learned friend Lord Mackay of Clashfern. He talked about the difficulties that the Government are facing and about these new versions of psychoactive substances that are coming on to the market. In fact, the European centre that monitors these things is identifying two new versions per week. More than 500 have been identified and banned since 2010. That is the difficulty that the noble Baroness, Lady Meacher, touched upon when she referred to temporary banning orders. We have tried those so we have some evidence that they do not work, because the minute we clamp down on one substance, up pop another one or two—or three or 10—somewhere else. The challenges that we face are clear.

Another point in the evidence—evidence that people have cited in all their contributions from their different perspectives on this—for the Government to take action on this is that we are seeing a general fall-off in the use of drugs, as the noble Lord, Lord Rosser, mentioned. The positive signs are there about the current approach to drugs. I will come back to this at some point but there has been an overemphasis on the Misuse of Drugs Act, which was a response to a series of international conventions, such as the UN convention. It recognised that the fight against narcotics and drugs was a global fight. We therefore introduced legislation but if there was just the Misuse of Drugs Act, as it was configured in 1971, there would of course be little support from any part of the House. The fact of the matter is that that is only one part of the legislation.

The noble Lord, Lord Patel of Bradford, talked about the excellent work being done in treatment and rehabilitation. There is work going on in education and very sophisticated work going on in policing, a point raised by the noble Lord, Lord Condon. In fact, having been a commander, the noble Lord, Lord Paddick, was at the centre of the challenge of finding new ways to tackle those issues through law enforcement. There is a whole suite of different ways in which we are tackling this but across the majority of drugs and age groups, there has been a long-term downward trend in drug use over the past decade, a point made by my noble friend Lord Blencathra. Among 11 to 15 year-olds, drug use has been falling since its peak in 2003. More people are recovering from their dependency now than in 2009-10, and the average waiting time to access treatment is now down to three days. As a result of such innovation, the work that has been done in that area is providing alternatives and treatment. However, enforcement is part of that.

I come to the point that against the downward trend that we are seeing, in one area we see that the opposite is actually the case: usage is increasing and the number of deaths has almost doubled. There were 120 deaths of young people in 2013, and all the evidence is that that trend is on the rise.

[Lord Paddick]

Of those 120 deaths, for how many were new psychoactive substances the sole cause and for how many was it a mixture of these with alcohol and other controlled drugs?

[Lord Bates]

I do not have an exact breakdown, but that is how the health—

[Lord Paddick]

I can assist the Minister, because in only 23 of those deaths did the post mortem find only psychoactive substances in the bloodstream. It is important that we get the facts straight in these cases.

--- Later in debate ---

[Lord Bates]

I certainly agree with the noble Baroness that the wider issue is not narrow, it is very broad, but what we are trying to do here with this Bill is very narrow. It is very focused and based on the evidence. The noble Baroness says that the two amendments are linked but distinct. Now she is a lawyer and I am not, but to me if they are linked then they cannot be distinct. They are linked in the sense that if they are both moved together, then one effect will be to have a review which will delay action being taken on this menace—or mischief, as the noble Lord, Lord Condon, said—which is happening up and down this country and through which people are suffering and dying. We need to take action and we are doing that on the basis of medical evidence, law enforcement evidence and evidence from the Local Government Association.

[Lord Paddick]

My Lords, the debate this afternoon has been passionate on both sides, and both sides of the argument seem to be equally committed to believing that their side is right. If ever there was an example of why we need an independent, evidence-based review, the debate this afternoon is it because everybody who has spoken in the Chamber this afternoon cannot possibly be right. We might agree to a review of the Misuse of Drugs Act, but people will then ask why we would want to link it to this piece of legislation. The noble Lord, Lord Condon, for whom I have a great deal of respect, raised this as an issue.

The fact is that somebody said that the definition of madness is to carry on doing exactly the same thing while expecting a different result. Some people brought forward evidence in this argument that prohibition and criminalisation of drugs do not work, which the Minister has countered. One of the campaigning organisations called Release, which no doubt has sent information to noble Lords, claims that the UK has the highest lifetime amphetamine and ecstasy use, the second-highest cocaine use and the fourth-highest lifetime cannabis use in Europe. Not everybody can be right on this and my real concern—there is some evidence which we will come to in future amendments when we consider the Irish situation—is that this Bill, or this approach of prohibition and criminalisation, actually makes things worse. It makes people less safe. It makes more people die. It gets more people addicted. What I am concerned about is, if we make even more drugs illegal, it will have completely the reverse effect to the one wanted by everybody in this House, which is to make it safer, to have fewer deaths and fewer people addicted. That is why this amendment is here. That is why this amendment is linked to this Bill and that is why I wish to test the opinion of the House.

--- Later in debate ---

[Lord Rosser]

We have an amendment in this group and it is not about post-legislative scrutiny. It calls for the Secretary of State to publish an annual report on new psychoactive substances and sets out some of the information that must be included in the report.

There is currently a real lack of data collected and published on new psychoactive substances and their impact. For example, the first indication of a new drug tends to come from a hospital admission. If this happens in the United Kingdom, the National Poisons Information Service is informed and it then advises the European Monitoring Centre for Drugs and Drugs Addiction. The EMCDDA tells the National Poisons Information Service of drugs detected elsewhere in Europe. However, the Home Office keeps its own lists, the main one being the forensic early warning system, and, to date, successive Ministers have been unable to explain the relationship between the EMCDDA list and the Home Office list, which suggests that data are not being collected and published in a consistent or helpful way. Similar problems arise with monitoring drug-related deaths and overdoses. No proper data are collected on drug deaths as the data we have rely on examining countless records, which is why they are often incomplete and take years to publish.

There is a significant problem, too, with hospital admissions. The National Poisons Information Service collects new drugs but does not collect data on all drug- related overdoes. We do not know how many hospital admissions result from taking these new substances. Nor do we know in how many cases new psychoactive substances were a factor for those needing to access mental health services. Anecdotal evidence suggests that legal highs are a major factor, especially for adolescent mental health services.

In their response to the expert panel, the Government accepted the importance of information on new psychoactive substances and that it should be shared systematically at both a local and national level in a timely manner. However, the Government did not appear to accept the current inadequacies in the information, including those to which I have referred.

The expert panel said that, with the rise in the availability of NPSs, coupled with possibilities for NPS market development via the internet, the UK drug scene had become increasingly complex and fractured, and that a number of information issues arose from this. These included,

“the difficulty for any one agency to keep to keep abreast of all the new developments … the acknowledgement that the Misuse of Drugs Act 1971 needs to be supplemented by other legislation has meant that more professional networks require information including trading standards … the current time lags involved between data collection and publication of data obtained by current networks mean these systems cannot be employed in the service of providing more timely early-warning-type information; and … the need to collect, analyse and distribute information in a more systematic and timely fashion to help inform policy and practice at both a national and local level”.

Frankly, the Government’s response did not address all these issues since there seems to be a view that the forensic early warning system’s annual report can fit the bill. In its recommendations, the expert panel says:

“There is a need to establish prevalence, evidence and harms associated with NPS”.

It suggests that we should:

“Develop detection and data collection tools across criminal justice and health services, and other relevant settings, for example, schools and universities”.

A recommendation refers to developing,

“internet tools to monitor internet activity around NPS”,

and to the need to:

“Record health and social harms related to NPS by utilising professional networks and other early warning systems … understand local markets, including through headshops, retail outlets, prisons and local police assessment”.

On enhancing the share of information on NPSs, the panel said:

“Sharing information at both local and national levels is essential in helping to achieve a reduction in the demand and supply of drugs and in promoting comprehensive and effective interventions”.

It is fairly clear from the report of the expert panel that it does not think enough is currently being done in the area of the provision of information. The purpose of this amendment, as I said at the beginning, is to provide for the Secretary of State to publish an annual report on new psychoactive substances. The amendment sets out, in not quite so extensive a list as that of my noble friend Lord Howarth of Newport, some of the information that should be included in that report.

I hope the Minister will reflect further on this issue—the importance of information on NPSs—and the adequacy of the current information and the systems and methods by which it is provided. Our amendment gives the Minister the opportunity to do just that and I hope it is an opportunity she will take.

[Lord Paddick]

My Lords, I waited until this moment to speak because it seemed unfair to comment on the amendment in the name of the noble Lord, Lord Rosser, without his having spoken to it first. I have some sympathy with what the Labour Party is proposing, but I prefer Amendments 4 and 6 proposed by the noble Baroness, Lady Meacher, for the very reason that she articulated. The market for new psychoactive substances and that for other substances covered by the Misuse of Drugs Act cannot be treated as separate. The whole reason for the existence of new psychoactive substances is the controlling of other drugs. There would be no need for people to develop so-called legal highs if they could get the high legally from controlled drugs. It is essential that the annual report includes exactly what the noble Baroness proposes: an assessment of the impact on health and the social harms brought about by the Misuse of Drugs Act and this Bill.

The noble Lord, Lord Howarth of Newport, gave a long list of things that could be included in the report. If everything he suggested was included, it might not only put the Government off producing the report but put me off reading it or trying to wade through it. I agree with the noble and learned Lord, Lord Mackay of Clashfern, that post-legislative scrutiny of a Bill such as this by a Joint Committee of both Houses would be appropriate, but it should not mean that there should not also be an annual report, because things are changing so quickly. We have heard from other noble Lords about how different drugs come into mode and out again. We therefore need an annual assessment of whether the legislation is still fit for purpose.

[Baroness Chisholm of Owlpen (Con)]

I am grateful to the noble Baroness, Lady Meacher, and the noble Lords, Lord Rosser and Lord Howarth, for setting out the case for their respective new clauses. In one way or another, these all require an annual report on the impact of the Bill, and we have covered a huge amount of ground. Let me say at the outset that good lawmaking absolutely dictates that all new legislation should be reviewed post implementation to consider its effectiveness, and this is no exception. We are committed to post-legislative review of all new primary legislation. I can therefore assure the noble Lords and the noble Baroness that the Government fully intend to carry out a review or reviews of this legislation, once implemented.

Of course, data are hugely important, and it is important that we take in all aspects of the Act. It is right that the evidence required to produce an adequate review of the Act is fully and carefully considered. However, it is really important to remember that, given the time lag of some of the key data sources, it is unlikely that any useful data will be available within the first year of the implementation of the Act. Such a review normally takes place three to five years after Royal Assent to allow for a rich source of data to be collected, particularly if we are going to collect the amount of data that I feel is important, as the noble Lord, Lord Howarth, suggested. Indeed, as my noble friend Lord Blencathra said, it takes time to collect the data. It is important for the departments to conduct a particular review to make sure that they have everything in place. Certainly, in this case, we would not want to wait three years to review this legislation.

Understanding the evidence for and against the different legislative options to tackle the growth of psychoactive substances was central to the terms of reference of the Home Office’s New Psychoactive Substances Review Expert Panel, set up by the Liberal Democrat Minister Norman Baker. Alongside the expert panel’s report, the Home Office also published an evidence review last autumn. This set out the available evidence at the time on psychoactive substances. The review examined the identification of new psychoactive substances, along with the characteristics of users and their motivations for using these substances. It also examined the market and the evidence of harms. The evidence review provides us with a good basis for understanding the extent of the market, the uses and the problems associated with new psychoactive substances, and for measuring any changes over time.

The noble Lord, Lord Howarth, also mentioned that it was necessary for a wide range of data to be collected on the prevalence of traditional illicit drug use and its related harms. While the evidence on psychoactive substances is less established, there are data on a number of previously unseen substances identified in the UK, as well as on the prevalence of the use of some types of psychoactive substances, related deaths and treatment demand. Of course, the monitoring of data, along with the way they are collected so that they can be strengthened to provide a more complete picture of the use and harms of psychoactive substances, will continue over the period until a full review is done.